When it comes to how you deploy your cash in the market, research shows that investing a lump sum is the best strategy most of the time. But does ‘most of the time’ include right now? Today’s article outlines how, in the current high-valuation market environment, dollar cost averaging may be the better deployment strategy, with the author noting that “while a lump sum invested at high valuations has shown a higher win rate, this approach has also led to a wider range of outcomes and not always in a good way.” For more, CLICK HERE.
With the number of exchange-traded funds trading in the U.S. approaching 2,000, how are investors to make fund selections from this vast array of options? Today’s article notes that “While the ETF landscape is big and growing by the day, some funds can be considered the best in their respective categories, and have the potential to maintain those perches over the long term” – and proceeds to highlight what may be the best-in-category funds from across an array of asset classes. For more, CLICK HERE.
Continued global economic expansion. Inflation picking up – leading to further interest rate hikes by the Fed. More muted returns – and higher volatility. And a reduced reward for risk. These features sum up the economic backdrop that Blackrock strategists see ahead for the second quarter and beyond – and underlie the three investment ideas highlighted in today’s article. Where might investors want to focus their attention when it comes to equities, fixed income and commodities? CLICK HERE.
The fund highlighted in today’s article “seeks to identify strong sectors, and within those sectors, to identify companies that have the greatest potential for growth.” And its strategy has paid off – the fund beat its benchmark for the past 12-month period and is expected to continue to exhibit strong performance for the remainder of this year and beyond. For more on this fund – which skews towards the types of smaller-cap, domestic companies that are more insulated from ongoing trade concerns – and its selection process, CLICK HERE.
While tech stocks have been the recipients of the bulk of investor attention for a while now, moving forward investors may want to turn their attention to some less sexy market stalwarts: bank stocks. Today’s article declares that “banks are likely one of the leaders in the next up leg and present lower risk than technology stocks.” What factors are converging to make bank stocks prime picks – and what types of bank stocks might investors want to consider adding to their portfolios? CLICK HERE.
“Gone are the simple days when investing with a conscience meant excluding alcohol, tobacco and firearms from a portfolio. Today’s impact investors want their investments to align with a more rigorous standard of good while achieving a maximum return,” notes the author of today’s article. So how can one go about trying to do good with their investments without having to sacrifice when it comes to returns? The author outlines a number of tips in that regard – including why impact investors may need to apply a “better than the rest” approach. For more, CLICK HERE.
What could be better than receiving generous – and secure – payouts from your stocks as you wait for their share price to (hopefully) appreciate? Today’s article highlights three dividend stocks that offer a combination of “mouth-watering yields and solid track records of distribution increases that should make any dividend lover happy.” For more on these three stocks sporting yields up to 13.5% – an integrated oil major and two master limited partnerships – CLICK HERE.
Non-alcoholic steatohepatitis (NASH) is expected to become the leading cause of all liver transplants by 2020 – and there is currently no approved treatment for it. As such, this once obscure disease has become a top area of focus for drug makers, and as today’s article notes, “NASH is also predicted to be the next huge market opportunity for the biopharmaceutical industry, with some forecasting a global market size of as much as $35 billion per year.” For investors looking to cash in on the NASH dash, the author highlights a number of biopharmaceutical stocks to consider. For more, CLICK HERE.
Why invest in a single factor ETF when you can invest in a multifactor ETF? As the author of today’s article notes, “Multifactor funds imitate active strategies that have been successful in the past and reduce risk by diversifying across those that tend to work at different times.” When it comes to selecting a multifactor fund, however, the author cautions that seemingly similar funds can actually behave quite differently for a number of reasons. He proceeds to delve into three multifactor ETFs, all of which he sees as solid options – but one of which might have a slight edge. CLICK HERE.
Against a backdrop of increased market volatility, interest in “safe haven” assets – including precious metals – is increasing. However, today’s article outlines how, “Despite gold’s luster as the place to hide your money during volatile market conditions, silver is more likely to benefit given current positions held by hedge funds.” What are hedge funds doing relative to gold and silver – and how might this activity result in a surge in silver prices if precious metals break out? CLICK HERE.